Investigational drug · Phase 2
GKL-006
Also called: iNKT cells
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas, Hepatocellular Carcinoma (HCC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "GKL-006"
First trial start
2025
Aug 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GKL-006", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Pancreatic Cancer
- Ductal Adenocarcinoma of Pancreas
- Hepatocellular Carcinoma (HCC)
- Unresectable Hepatocellular Cancer
Approved drugs for the same conditions: Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "GKL-006" as an intervention, largest first.
Beijing Gene Key Life Technology Co., LtdIndustry
NCT07777211 · 52 participants (planned) · Start Aug 14, 2025 · Primary completion Mar 31, 2027
Drug: GKL-006 injection; Nab-paclitaxel and Gemcitabine · For: Advanced Pancreatic Cancer; Ductal Adenocarcinoma of Pancreas
Sites: Beijing, China
- GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruiting
Beijing Gene Key Life Technology Co., LtdIndustry
NCT07209813 · 48 participants (planned) · Start Nov 14, 2025 · Primary completion Sep 30, 2027
Drug: GKL-006 Injection · For: Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Cancer
Sites: Beijing, China; Zhengzhou, China; Changsha, China · 7 sites in all
Beijing Gene Key Life Technology Co., LtdIndustry
NCT07845266 · 13 participants · Start Apr 16, 2024 · Primary completion Apr 9, 2025
Drug: GKL-006 Injection; transarterial chemoembolization · For: Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Carcinoma
Sites: Beijing, China · 2 sites in all
- A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular CarcinomaActive, not recruiting
Beijing Gene Key Life Technology Co., LtdIndustry
NCT07713290 · 6 participants · Start Apr 3, 2025 · Primary completion Nov 12, 2026
Drug: GKL-006 Injection · For: Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Cancer
Sites: Beijing, China; Taiyuan, China · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The CD1d-iNKT Axis Modulates Allergic Responses to Alpha-Gal.
Wang Y, Rival CM, Zhang Y, et al. · Clin Exp Allergy 2026
- Artificial intelligence-driven precision immunogenetics for cancer stem cell-targeted CAR immunotherapy.
Abeysuriya V, Alwis SN, Abeysuriya V · J Egypt Natl Canc Inst 2026
- Fully synthetic arecoline and arecaidine vaccine candidates with α-Galactosylceramide as built-in adjuvant.
Huang SQ, Chen XZ, Chen LY, et al. · Eur J Med Chem 2026
- HER2 CAR-expressing iPSC-derived iNKT cells exhibit multifaceted immunomodulatory functions beyond direct tumor killing.
Shioya K, Matsumura T, Urakami A, et al. · J Immunother Cancer 2026
- Ex vivo expansion reshapes invariant natural killer T-cell state, function, and therapeutic fitness.
Tavakolinia N · Clin Immunol 2026
- Alpha-galactosylceramide as mRNA vaccine adjuvant modulates cellular immunity against tuberculosis and contributes to antigen-specific lung-associated T cells with a TRM-associated phenotype following prime-pull strategy.
Aernout I, Ehouarne T, Mwangi K, et al. · Front Immunol 2026
Also in development for Advanced Pancreatic Cancer
- LM-108Phase 36 trials
LaNova Medicines Limited · Advanced Solid Tumor, Advanced Pancreatic Cancer, Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
- MRG004APhase 31 trial
Lepu Biopharma Co., Ltd. · Advanced Pancreatic Cancer
- BotensilimabAGEN1181, 8541APhase 24 trials
Agenus Inc. · Metastatic Colorectal Cancer, Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), Untreated
- NLM-001Phase 22 trials
Nelum Corp · Untreated, Advanced Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
- BalstililmabPhase 21 trial
Nelum Corp · Untreated, Advanced Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.